Fixed-duration pirtobrutinib and obinutuzumab for untreated CLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, pirtobrutinib (a pill) and obinutuzumab (an infusion), given for a set period of time in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had any previous treatment for their disease. The goal is to see if this combination can control the cancer effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have CLL or SLL that needs treatment now and has not been treated before.
- You must have measurable disease, such as a high lymphocyte count, enlarged lymph nodes, or bone marrow involvement.
- You must be 18 years or older.
- You must be able to take oral medications and have adequate organ and bone marrow function.
- You must not have had any prior therapy for CLL or SLL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
This trial tests a combination of two targeted drugs, zanubrutinib (a pill) and obinutuzumab (an infusion), for people with untreated CLL or SLL who need treatment. The goal is to see if this combination works well and is safe.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
This Phase 3 trial compares two oral medicines—pirtobrutinib and ibrutinib—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need treatment. It’s designed to see which drug works better and is easier to take, especially for people with a specific genetic change in the cancer (17p deletion).
This trial tests a new drug, pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) who have already been treated with zanubrutinib (a similar BTK inhibitor). The goal is to see if switching to pirtobrutinib can help control the disease.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.